Trial · NCT03118739
Outcomes43
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 43
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Urinary Albumin to Creatinine Ratio (UACR) | From Baseline to 12 Weeks of Treatment | Number analyzed at 12 weeks was less than the overall number analyzed due to missing observations | Precent change | LEAST_SQUARES_MEAN |
| SECONDARY | sUA | From Baseline to 12 Weeks and 24 Weeks of Treatment | Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations | Percent change | LEAST_SQUARES_MEAN |
| SECONDARY | eGFR | From Baseline to 12 Weeks and 24 Weeks of Treatment | Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations | Percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Serum Creatinine | From Baseline to 12 Weeks and 24 Weeks of Treatment | Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations | Percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Serum Cystatin C | From Baseline to 12 Weeks and 24 Weeks of Treatment | Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations | Percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Serum High Sensitivity C-reactive Protein | From Baseline to 12 Weeks and 24 Weeks of Treatment | Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations | Percent change | LEAST_SQUARES_MEAN |
| SECONDARY | Clinical Assessments | From Baseline to 12 Weeks and 24 Weeks of Treatment | Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations | mm/Hg | MEAN |
| SECONDARY | MRI Variables - LV Mass/End-diastolic Volume | From Baseline to 24 Weeks of Treatment | Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations | g/mL | MEAN |
| OTHER_PRE_SPECIFIED | Flow Mediated Dilatation (Reactive Hyperemia) | From Baseline to 12 Weeks and 24 Weeks of Treatment | Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations | Units on a scale | LEAST_SQUARES_MEAN |
| OTHER_PRE_SPECIFIED | Urinalysis | From Baseline to 12 Weeks and 24 Weeks of Treatment | Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations | mg/dL | MEAN |
| OTHER_PRE_SPECIFIED | Clinical Chemistry Values | From Baseline to 12 Weeks and 24 Weeks of Treatment | Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations | pmol/L | MEAN |
| PRIMARY | Urinary Albumin to Creatinine Ratio (UACR) Compared to Placebo | From Baseline to 24 Weeks of Treatment | Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations | Precent change | LEAST_SQUARES_MEAN |
| SECONDARY | MRI Variables - Kidney Cortex T2 Star - BOLD MRI | From Baseline to 24 Weeks of Treatment | Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations | ms | MEAN |
| SECONDARY | MRI Variables - LV End-diastolic Volume, LV End-systolic Volume, LV Stroke Volume | From Baseline to 24 Weeks of Treatment | Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations | mL | MEAN |
| SECONDARY | MRI Variables - LV Ejection Fraction, Circumferential Strain, Longitudinal Strain, Radial Strain | From Baseline to 24 Weeks of Treatment | Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations | % (change in percentage from baseline) | MEAN |
| SECONDARY | MRI Variables - Diastolic Circumferential Strain Rate, Longitudinal Strain Rate, Radial Strain Rate and Systolic Circumferential Strain Rate, Longitudinal Strain Rate, Radial Strain Rate | From Baseline to 24 Weeks of Treatment | Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations | s^-1 | MEAN |
| SECONDARY | MRI Variables - LV Mass | From Baseline to 24 Weeks of Treatment | Number analyzed at 24 weeks was less than the overall number analyzed due to missing observations | g | MEAN |
| OTHER_PRE_SPECIFIED | Urinalysis | From Baseline to 12 Weeks and 24 Weeks of Treatment | Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations | mg/g | MEAN |
| OTHER_PRE_SPECIFIED | Clinical Chemistry Values | From Baseline to 12 Weeks and 24 Weeks of Treatment | Number analyzed at 12 and 24 weeks was less than the overall number analyzed due to missing observations | % hemoglobin bound to glucose | MEAN |
| OTHER_PRE_SPECIFIED | Baseline eGFR | Baseline | mL/min/1.73m2 | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03118739/outcomes